Speaker illustration

Doctor Ahmed A Kolkailah

University of Texas Southwestern Medical Center, Dallas (United States of America)

Effects of once-weekly semaglutide on coronary outcomes in patients with type 2 diabetes mellitus with or at high risk for cardiovascular disease: insights from the SUSTAIN-6 trial

Event: ESC Preventive Cardiology 2022

Topic: Pharmacotherapy

Session: Rapid fire abstracts session 1 - Secondary Prevention and Rehabilitation

Thumbnail

This platform is supported by

logo Novo Nordisk